Back دولاجلوتيد Arabic Dulaglutid German Ντουλαγλουτίδη Greek Dulaglutida Spanish دولاگلوتاید Persian Dulaglutidi Finnish Dulaglutide French Dulaglutide Italian ଡୁଲାଗ୍ଲୁଟାଇଡ OR Dulaglutyd Polish

Dulaglutide

Dulaglutide
Autoinjector with Trulicity by Lilly
Clinical data
Trade namesTrulicity, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa614047
License data
Pregnancy
category
Routes of
administration		Subcutaneous
Drug classIncretin mimetics
ATC code
Legal status
Legal status
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC2646H4044N704O836S18
Molar mass59670.63 g·mol−1

Dulaglutide, sold under the brand name Trulicity among others,[8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise.[9][10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.[11]

The most common side effects are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.[8]

It is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. GLP-1 is a hormone that is involved in normalizing the level of glucose in blood (glycemia). The Food and Drug Administration (FDA) approved dulaglutide for use in the United States in September 2014.[8][12] It was approved for use in the European Union in November 2014.[7] In 2022, it was the 74th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[13][14]

  1. ^ "Dulaglutide international". Drugs.com. 3 January 2020. Retrieved 4 February 2020.
  2. ^ "Dulaglutide (Trulicity) Use During Pregnancy". Drugs.com. 15 July 2019. Retrieved 4 February 2020.
  3. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  4. ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  5. ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
  6. ^ "Trulicity- dulaglutide injection, solution". DailyMed. 3 January 2024. Retrieved 26 August 2024.
  7. ^ a b "Trulicity EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 23 February 2020.
  8. ^ a b c "FDA approves Trulicity to treat type 2 diabetes" (Press release). U.S. Food and Drug Administration (FDA). 18 September 2014. Archived from the original on 20 April 2016. Retrieved 4 February 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  9. ^ Tibble CA, Cavaiola TS, Henry RR (May 2013). "Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature". Expert Review of Endocrinology & Metabolism. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
  10. ^ "Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes" (Press release). Eli Lilly. 25 February 2014.
  11. ^ "Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease". Eli Lilly and Company (Press release). 21 February 2020. Retrieved 23 February 2020.
  12. ^ "Drug Approval Package: Trulicity (dulaglutide) NDA #125469". U.S. Food and Drug Administration (FDA). 27 October 2014. Retrieved 4 February 2020.
  13. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  14. ^ "Dulaglutide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

Developed by StudentB